# 1.0 Submitted By:

Marine Boyajian   
Senior Regulatory Affairs Specialist Beckman Coulter, Inc.   
200 S. Kraemer Blvd., W-110   
Brea, California 92822-8000   
Telephone: (714) 961-6536   
FAX: (714) 961-4234

# 2.0 Date Submitted:

June 19, 2009

# 3.0 Device Name(s):

3.1 Proprietary Names SYNCHRON® Systems G7 Amylase (AMY7) Reagent

3.2 Classification Name Amylase test system (21 CFR $\ S$ 862.1070)

# 4.0 Predicate Device:

<table><tr><td rowspan=1 colspan=1>Candidate(s)</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>DocketNumber</td></tr><tr><td rowspan=1 colspan=1>SYNCHRON Systems G7Amylase (AMY7) Reagent</td><td rowspan=1 colspan=1>Amylase EPS Reagent</td><td rowspan=1 colspan=1>Thermo FisherScientific, Inc.</td><td rowspan=1 colspan=1>K070064</td></tr></table>

# 5.0 Description:

AMY7 reagent is used to measure the amylase activity by an enzymatic rate method. The system monitors the change in absorbance at 410 nanometers. This change in absorbance is directly proportional to the activity of AMY7 in the sample and is used by the System to calculate and express the total AMY7 activity.

The SYNCHRON G7 Amylase (AMY7) Reagent is designed for optimal performance on the SYNCHRON $L X ^ { \circledast }$ ,UniCel® DxC 600/800, and SYNCHRON $\operatorname { \dot { C } } X ^ { \circledast }$ PRO Clinical Systems. The reagent kit contains two 200-test cartridges.

AMY7 reagent, in conjunction with SYNCHRON® System(s) and UniCe® DxC System(s), is intended for the quantitative determination of total Amylase activity in human serum, plasma or urine.

Amylase measurements are used primarily in the diagnosis and treatment of pancreatitis.

# 7.0 Comparison to Predicate(s):

The following table shows similarities and differences between the predicate identified in Section 4.0 of this summary and the G7 Amylase (AMY7) Reagent.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Similarities</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=6 colspan=1>SYNCHRONSystems G7Amylase(AMY7)Reagent</td><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument Platforms</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Primary DetectionWavelength</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Type(Methodology)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Volume</td><td rowspan=1 colspan=1>AMY7 Reagent:−Compartment A: 175 μlCompartment B: 35 μlEPS-G7 Reagent: Compartment A: 175 μlCompartment B:35 μl</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Differences</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=3 colspan=1>SYNCHRONSystems G7Amylase(AMY7)Reagent</td><td rowspan=1 colspan=1>Analytical range(Serum/Plasma/ Urine)</td><td rowspan=1 colspan=1>AMY7 Reagent:  8 - 1200 U/L on CX PRO5 - 1200 U/L on LX/DxC1000 - 2000 U/L ORDACEPS-G7 Reagent: 4 - 1800 U/L on CX4 - 2000 U/L on LX/DxC</td></tr><tr><td rowspan=1 colspan=1>Open reagent stability</td><td rowspan=1 colspan=1>AMY7 Reagent:  21 daysEPS-G7 Reagent: 35 days</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>AMY7 Reagent:7μl3 pI ORDACEPS-G7 Reagent: 7 μl</td></tr></table>

# 8.0 Summary of Performance Data:

The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to chemistry test systems already in commercial distribution. Equivalence is demonstrated through method comparison, stability, linearity, and imprecision experiments.

Serum Method Comparison Summary   

<table><tr><td rowspan=1 colspan=1>Candidate.7</td><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>Slope,   .i  .</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R&#x27;</td><td rowspan=1 colspan=1>N.:</td><td rowspan=1 colspan=1>PredicateMethod</td></tr><tr><td rowspan=2 colspan=1>G7 Amylase(AMY7) Reagent</td><td rowspan=1 colspan=1>CX7 PRO</td><td rowspan=1 colspan=1>1.150</td><td rowspan=1 colspan=1>-4.089</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>87</td><td rowspan=2 colspan=1>Thermo FisherAmylase EPS -G7 Reagent</td></tr><tr><td rowspan=1 colspan=1>DxC 600</td><td rowspan=1 colspan=1>1.081</td><td rowspan=1 colspan=1>-3.364</td><td rowspan=1 colspan=1>1.0000</td><td rowspan=1 colspan=1>83</td></tr></table>

Urine Method Comparison Summary   

<table><tr><td rowspan=1 colspan=1>Candidate</td><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>PredicateMethod</td></tr><tr><td rowspan=2 colspan=1>G7 Amylase(AMY7) Reagent</td><td rowspan=1 colspan=1>CX7 PRO</td><td rowspan=1 colspan=1>1.109</td><td rowspan=1 colspan=1>-2.086</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>78</td><td rowspan=2 colspan=1>Thermo FisherAmylase EPS -G7 Reagent</td></tr><tr><td rowspan=1 colspan=1>DxC 600</td><td rowspan=1 colspan=1>1.039</td><td rowspan=1 colspan=1>-0.703</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>78</td></tr></table>

# SYNCHRON Systems G7 Amylase (AMY7) Reagent Precision Study Results

Precision Study Results on SYNCHRON CX7 PRO Clinical System   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>S.D.(U/L)   :</td><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=5>Within-Run Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 1</td><td rowspan=1 colspan=1>75.8</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 2</td><td rowspan=1 colspan=1>899.5</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    (ORDAC)</td><td rowspan=1 colspan=1>1762.0</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 1</td><td rowspan=1 colspan=1>54.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 2</td><td rowspan=1 colspan=1>164.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               (ORDAC)</td><td rowspan=1 colspan=1>1182.9</td><td rowspan=1 colspan=1>11.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=5>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 1</td><td rowspan=1 colspan=1>75.8</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 2</td><td rowspan=1 colspan=1>899.5</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    (ORDAC)</td><td rowspan=1 colspan=1>1762.0</td><td rowspan=1 colspan=1>34.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 1</td><td rowspan=1 colspan=1>54.9</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 2</td><td rowspan=1 colspan=1>164.6</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine                (ORDAC)</td><td rowspan=1 colspan=1>1182.9</td><td rowspan=1 colspan=1>60.4</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>80</td></tr></table>

Precision Study Results on UniCel DxC 600 SYNCHRON Clinical System   

<table><tr><td rowspan=1 colspan=1>Sample        57</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>S.D.(U/L)</td><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=5>Within-Run Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 1</td><td rowspan=1 colspan=1>78.7</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 2</td><td rowspan=1 colspan=1>913.6</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    (ORDAC)</td><td rowspan=1 colspan=1>1775.4</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 1</td><td rowspan=1 colspan=1>56.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 2</td><td rowspan=1 colspan=1>168.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               (ORDAC)</td><td rowspan=1 colspan=1>1181.0</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=5>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 1</td><td rowspan=1 colspan=1>78.7</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    Level 2</td><td rowspan=1 colspan=1>913.6</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma    (ORDAC)</td><td rowspan=1 colspan=1>1775.4</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 1</td><td rowspan=1 colspan=1>56.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               Level 2</td><td rowspan=1 colspan=1>168.4</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Urine               (ORDAC)</td><td rowspan=1 colspan=1>1181.0</td><td rowspan=1 colspan=1>55.5</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>80</td></tr></table>

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CF R 807.92.

Beckman Coulter, Inc.   
ATTN: Ms. Marine Boyajian   
Senior Regulatory Affairs Specialist 200 South Kraemer Blvd. W-110 Brea, CA 92822

OCT 1 6 2009

Re: k091846 Trade/Device Name: Synchron $\textsuperscript { \textregistered }$ Systems G7 Amylase (AMY7) Reagent Regulation Number: 21 CFR $\ S 8 6 2 . 1 0 7 0$ Regulation Name: Amylase test system. Regulatory Class: Class II Product Code: JFJ Dated: September 11, 2009 Received: September 14, 2009

Dear Ms. Boyajian:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/ed6907cf1cd567467560c8065ab9932ae1824b4dc859f537804fe83ae666e975.jpg)

Courtnty C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number: k091846

Device Name: SYNCHRON® Systems G7 Amylase (AMY7) Reagent

Indication For Use:

AMY7 reagent, in conjunction with SYNCHRON® System(s) and UniCe® DxC System(s), is intended for the quantitative determination of total Amylase activity in human serum, plasma or urine.

Amylase measurements are used primarily in the diagnosis and treatment of pancreatitis.

Concurnce  CDRH, Office of In Vit Diagnosti DevicEvaluaton and Safety (OIVD)

![](images/db07db8961b4d40f1164cdb132cdecb798dd54fcfff86291a9fd0296eaf80de0.jpg)

Diyision Sigh-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety